Abstract: The present invention relates to a composition for preventing or treating transplantation rejection or a transplantation rejection disease, comprising a novel compound and a calcineurin inhibitor. A co-administration of the present invention 1) reduces the activity of pathogenic Th1 cells or Th17 cells, 2) increases the activity of Treg cells, 3) has an inhibitory effect against side effects, such as tissue damage, occurring in the sole administration thereof, 4) inhibits various pathogenic pathways, 5) inhibits the cell death of inflammatory cells, and 6) increases the activity of mitochondria, in an in vivo or in vitro allogenic model, a transplantation rejection disease model, a skin transplantation model, and a liver-transplanted patient, and thus inhibits transplantation rejection along with mitigating side effects possibly occurring in the administration of a conventional immunosuppressant alone.

Abstract: The present disclosure relates to a plurality of host materials, an organic electroluminescent compound, and an organic electroluminescent device comprising the same. By comprising a specific combination of host compounds and/or an organic electroluminescent compound according to the present disclosure as an organic electroluminescent material, an organic electroluminescent device having low driving voltage and/or high luminous efficiency and/or long lifespan characteristics can be provided.

Abstract: The present disclosure relates to an organic electroluminescent compound and an organic electroluminescent device comprising the same. By comprising the compound according to the present disclosure, it is possible to produce an organic electroluminescent device having improved driving voltage, power efficiency, and/or lifetime properties compared to the conventional organic electroluminescent devices.

Abstract: In one example, a semiconductor device can comprise a substrate, a device stack, first and second internal interconnects, and an encapsulant. The substrate can comprise a first and second substrate sides opposite each other, a substrate outer sidewall between the first substrate side and the second substrate side, and a substrate inner sidewall defining a cavity between the first substrate side and the second substrate side. The device stack can be in the cavity and can comprise a first electronic device, and a second electronic device stacked on the first electronic device. The first internal interconnect can be coupled to the substrate and the device stack. The encapsulant can cover the substrate inner sidewall and the device stack and can fill the cavity. Other examples and related methods are disclosed herein.

Abstract: Disclosed herein is a composition for enhancing skin elasticity or improving skin wrinkles. In one aspect, 2-isopropylmalic acid or a salt, hydrate or solvate thereof, which is an active ingredient of the present disclosure, activates skin primary cilia and inhibits the expression of MMP-1 to enhance skin elasticity and improve skin wrinkles. In addition, in one aspect, 2-isopropylmalic acid or a salt, hydrate or solvate thereof, which is an active ingredient of the present disclosure, is a safe material and has the advantage that it can be treated in the living body in various forms such as cosmetics and food.

Abstract: The present invention relates to a single nucleotide polymorphism (SNP) for predicting the sensitivity to an anticancer targeted therapeutic formulation, a polynucleotide containing the same, and a method for predicting the sensitivity to an anticancer targeted therapeutic formulation. According to the present invention, it is possible to predict the sensitivity of each individual to a certain anticancer targeted therapeutic formulation, using a small amount of a sample taken from a patient and thus to select a most suitable targeted therapeutic formulation over the entire duration of treatment for the patient.